By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair said today it has initiated coverage of Illumina's stock, giving it an "outperform" rating.

It also gave San Diego-based Illumina an "aggressive growth" company profile. Amanda Murphy, an analyst at William Blair, estimated a $1.06 earnings per share price for 2010, a $1.46 EPS for 2011, and a $1.93 EPS for 2012.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.